View Clinical Trial (Medical Research Study)
Genetic Modifiers for 22q11.2 Syndrome
| City: |
|
Syracuse |
| State: |
|
New York |
| Zip Code: |
|
13210 |
| Conditions: |
|
22q11.2 Deletion Syndrome |
| Purpose: |
|
The purpose of the project is the determination of how the deletion of DNA from chromosome
22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS).
In other words, the purpose remains genotype-to-phenotype matching. Current methods
includes the use of whole genome chips and microarray analysis. Blood samples are collected
for DNA from every patient who consents from the VCFS Center at Upstate Medical University.
They are examined for phenotypic features consistent with our typical clinical evaluation.
The information from these examinations will be entered anonymously into a database.
Genomic information is then matched to clinical phenotype with appropriate statistical
method applied.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- FISH confirmed diagnosis of 22q11.2 deletion syndrome
Exclusion Criteria:
- none
|
| NCT ID: |
|
NCT00916955 |
| Primary Contact: |
|
Principal Investigator Robert J Shprintzen, PhD Upstate Medical University
Anne Marie Higgins, RN, FNP, MA Phone: 315-464-6595 Email: HigginsA@upstate.edu
|
| Backup Contact: |
|
Email: shprintr@upstate.edu Robert J Shprintzen, PhD Phone: 315-464-6590
|
| Location Contact: |
|
Syracuse, New York 13210 United States
Anne Marie Higgins, RN, FNP, MA Phone: 315-464-6595 Email: HigginsA@upstate.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|